The Health and Safety Executive (HSE) has announced a pivotal regulatory update concerning the biocide sector. On 19 February 2024, an ebulletin was released detailing the extension of expiry dates for all biocidal active substance and product type combinations initially set to expire between the start of 2024 and the end of 2026. This extension pushes the expiry dates to 31 January 2027, affecting up to 110 combinations.
Reasons for the Extension
The HSE's decision is primarily due to the realization that, without this intervention, many approvals would likely expire before a renewal could be assessed under the current GB Biocidal Products Regulation (GB BPR). By postponing these dates, the HSE aims to provide sufficient time to consider potential reforms to the GB BPR. The organization has indicated plans to release more information on this topic in the near future.
Impact and Requirements
As of now, 46 active substance/product type combinations have successfully met the criteria for this extension, with their specifics accessible on the HSE website. The range of substances includes those used in pest control, material preservation, and various other applications. The extension is conditional upon the timely submission and acceptance of a renewal application.
Substances Affected by the Postponement
Some of the notable substances whose expiry dates have been postponed include Copper (II) hydroxide, Hydrochloric acid, and Cholecalciferol, among others. These substances are used in a broad spectrum of products, from rodenticides to preservatives and insecticides.
Guidance for Manufacturers
Manufacturers interested in introducing new biocidal products containing these active substances into the GB market are advised that they can proceed with applications for GB BPR product authorisation. However, it is critical that these products, including those under new trade names, are not supplied within GB until they have been officially authorised.
Future Updates and Implications
The HSE commits to providing timely updates on any further postponements within this decision's scope. This regulatory adjustment not only offers a reprieve to industry stakeholders but also highlights the HSE's commitment to a balanced regulatory approach that considers the complexities of the approval process while protecting public and environmental health.
This extension provides industries with additional time to align with regulatory standards amidst ongoing discussions and potential reforms to the GB BPR framework. Stakeholders are encouraged to stay informed on future developments to navigate the regulatory landscape effectively.
